Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplastic Stem Cells | 17 | 2025 | 202 | 5.770 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 18 | 2019 | 72 | 5.290 |
Why?
|
| Fusion Proteins, bcr-abl | 9 | 2019 | 35 | 1.690 |
Why?
|
| Leukemia | 2 | 2025 | 62 | 1.420 |
Why?
|
| Stem Cells | 2 | 2025 | 259 | 0.990 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2025 | 189 | 0.920 |
Why?
|
| Arachidonate 5-Lipoxygenase | 4 | 2016 | 9 | 0.850 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 163 | 0.790 |
Why?
|
| Polycythemia Vera | 2 | 2025 | 6 | 0.770 |
Why?
|
| Janus Kinase 2 | 2 | 2025 | 15 | 0.770 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2025 | 284 | 0.740 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2010 | 84 | 0.720 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 68 | 0.670 |
Why?
|
| Signal Transduction | 8 | 2022 | 3020 | 0.660 |
Why?
|
| Lymph Nodes | 1 | 2020 | 222 | 0.650 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 198 | 0.650 |
Why?
|
| Mice | 19 | 2025 | 10802 | 0.640 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 178 | 0.630 |
Why?
|
| src-Family Kinases | 3 | 2013 | 63 | 0.580 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2019 | 187 | 0.580 |
Why?
|
| Animals | 22 | 2025 | 20579 | 0.580 |
Why?
|
| Benzamides | 7 | 2014 | 65 | 0.560 |
Why?
|
| Piperazines | 7 | 2014 | 76 | 0.550 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2012 | 72 | 0.550 |
Why?
|
| Pyrimidines | 7 | 2014 | 135 | 0.540 |
Why?
|
| Imatinib Mesylate | 8 | 2019 | 34 | 0.530 |
Why?
|
| Membrane Proteins | 2 | 2012 | 889 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 194 | 0.460 |
Why?
|
| Mice, Knockout | 7 | 2016 | 2097 | 0.450 |
Why?
|
| Disease Models, Animal | 5 | 2016 | 2173 | 0.410 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 660 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 7 | 2016 | 3387 | 0.390 |
Why?
|
| Antigens, Ly | 1 | 2012 | 42 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2012 | 32 | 0.390 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2012 | 10 | 0.390 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 34 | 0.370 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2011 | 6 | 0.370 |
Why?
|
| Cell Lineage | 1 | 2012 | 268 | 0.350 |
Why?
|
| Hypoxia | 1 | 2012 | 113 | 0.350 |
Why?
|
| Cell Cycle | 2 | 2013 | 392 | 0.350 |
Why?
|
| Apoptosis | 2 | 2012 | 1066 | 0.330 |
Why?
|
| Myeloproliferative Disorders | 1 | 2009 | 15 | 0.330 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 125 | 0.310 |
Why?
|
| Humans | 19 | 2025 | 62653 | 0.300 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2015 | 51 | 0.300 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2012 | 65 | 0.250 |
Why?
|
| Carrier Proteins | 1 | 2009 | 705 | 0.230 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 86 | 0.220 |
Why?
|
| Hydroxyurea | 2 | 2016 | 19 | 0.220 |
Why?
|
| Blotting, Western | 2 | 2016 | 610 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 303 | 0.200 |
Why?
|
| Oxidative Phosphorylation | 1 | 2022 | 41 | 0.200 |
Why?
|
| Flow Cytometry | 2 | 2016 | 669 | 0.200 |
Why?
|
| Hedgehog Proteins | 2 | 2015 | 111 | 0.190 |
Why?
|
| Cell Survival | 2 | 2015 | 573 | 0.190 |
Why?
|
| K562 Cells | 2 | 2012 | 57 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 893 | 0.190 |
Why?
|
| Genes, abl | 2 | 2012 | 9 | 0.180 |
Why?
|
| Hematoxylin | 1 | 2020 | 11 | 0.180 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2020 | 12 | 0.180 |
Why?
|
| Coloring Agents | 1 | 2020 | 54 | 0.170 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 2 | 2010 | 2 | 0.170 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 2010 | 4 | 0.170 |
Why?
|
| Microscopy | 1 | 2020 | 91 | 0.170 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 229 | 0.170 |
Why?
|
| Staining and Labeling | 1 | 2020 | 126 | 0.170 |
Why?
|
| Thiazolidines | 1 | 2019 | 14 | 0.160 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 32 | 0.160 |
Why?
|
| Biopsy | 1 | 2020 | 429 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2014 | 981 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2020 | 562 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 129 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 761 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 963 | 0.140 |
Why?
|
| Hospitals | 1 | 2020 | 392 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 324 | 0.140 |
Why?
|
| Research | 1 | 2019 | 192 | 0.140 |
Why?
|
| Leukotriene Antagonists | 1 | 2016 | 7 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 25 | 0.130 |
Why?
|
| Mutation | 1 | 2025 | 2573 | 0.130 |
Why?
|
| Ceramides | 1 | 2016 | 25 | 0.130 |
Why?
|
| Cells, Cultured | 2 | 2011 | 2154 | 0.120 |
Why?
|
| Retroviridae | 1 | 2016 | 73 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 453 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 515 | 0.120 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 152 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 266 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2013 | 9 | 0.100 |
Why?
|
| GA-Binding Protein Transcription Factor | 1 | 2013 | 16 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2014 | 375 | 0.100 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 17 | 0.100 |
Why?
|
| PAX5 Transcription Factor | 1 | 2012 | 13 | 0.100 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2014 | 576 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 31 | 0.100 |
Why?
|
| Gamma Rays | 1 | 2012 | 32 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 43 | 0.100 |
Why?
|
| Fluorouracil | 1 | 2012 | 66 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2013 | 152 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 52 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 102 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2012 | 76 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 139 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 206 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2011 | 63 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 220 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 165 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2012 | 318 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2012 | 348 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 297 | 0.090 |
Why?
|
| Dasatinib | 1 | 2010 | 4 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 544 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2012 | 310 | 0.090 |
Why?
|
| Philadelphia Chromosome | 1 | 2010 | 3 | 0.080 |
Why?
|
| Harringtonines | 1 | 2010 | 1 | 0.080 |
Why?
|
| Thiazoles | 1 | 2010 | 47 | 0.080 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2010 | 8 | 0.080 |
Why?
|
| Cell Transplantation | 1 | 2010 | 39 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 431 | 0.080 |
Why?
|
| Imidazoles | 1 | 2010 | 80 | 0.080 |
Why?
|
| Survival Rate | 1 | 2012 | 839 | 0.080 |
Why?
|
| Point Mutation | 1 | 2010 | 165 | 0.080 |
Why?
|
| Disease Progression | 2 | 2014 | 1159 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2010 | 66 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2010 | 100 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 520 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2015 | 675 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 237 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 206 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 670 | 0.070 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 236 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1184 | 0.070 |
Why?
|
| Biomarkers | 1 | 2012 | 1382 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1528 | 0.060 |
Why?
|
| Cell Line | 1 | 2010 | 2038 | 0.060 |
Why?
|
| Time Factors | 1 | 2012 | 3740 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1180 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2019 | 937 | 0.060 |
Why?
|
| Alleles | 1 | 2025 | 445 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 288 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2025 | 888 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 502 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2022 | 146 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2022 | 293 | 0.040 |
Why?
|
| Prognosis | 1 | 2025 | 1724 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 427 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 2019 | 10 | 0.040 |
Why?
|
| Leukemia, Experimental | 1 | 2019 | 19 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 82 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2022 | 1346 | 0.030 |
Why?
|
| Male | 2 | 2025 | 29472 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 5403 | 0.030 |
Why?
|
| raf Kinases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 24 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 57 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 72 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 103 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 201 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1451 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 836 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1271 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 14249 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 898 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 16623 | 0.020 |
Why?
|
| Middle Aged | 1 | 2025 | 17358 | 0.020 |
Why?
|
| Female | 1 | 2025 | 32478 | 0.010 |
Why?
|